Seattle, Washington, USA – May 21, 2026
HDT Bio and The University of Texas Medical Branch (UTMB) have received the prestigious Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award for advancing their lead biodefense vaccine candidate HDT-321 from laboratory development into a Phase 1 clinical trial. The recognition highlights the growing importance of next-generation vaccine technologies in addressing emerging infectious diseases and global biodefense threats. The award-winning program focuses on the development of vaccines targeting Crimean-Congo Hemorrhagic Fever (CCHF) and Henipaviruses, both considered serious global public health concerns with pandemic potential.
The MCDC Innovation Prototype Award is presented annually to acknowledge exceptional innovation in the development of medical countermeasures supporting defense against chemical, biological, radiological, and nuclear threats. For HDT Bio, the achievement represents a major milestone in translating advanced vaccine science into clinical-stage development while strengthening preparedness against highly dangerous viral diseases.
HDT-321 Progresses From Research to Human Clinical Studies
HDT-321 is a clinical-stage prophylactic vaccine candidate designed to protect against Crimean-Congo Hemorrhagic Fever, one of the world’s most widespread viral hemorrhagic fevers. CCHF is primarily transmitted through infected tick bites and contact with infected animals, and scientists warn that warming climates and expanding tick habitats are contributing to the disease’s spread into new geographic regions. The virus is associated with high mortality rates and remains a major emerging infectious disease concern globally.
Supported by the MCDC, the U.S. Department of War, the National Institute of Allergy and Infectious Diseases (NIH/NIAID), and UTMB, HDT Bio conducted extensive preclinical research at NIH/NIAID’s Rocky Mountain Laboratories in Montana. According to the company, HDT-321 demonstrated strong protection against CCHF virus infection in preclinical models, supporting further advancement into human clinical investigation.
Advertisement
The vaccine is built on HDT Bio’s proprietary LION™ delivery platform, a technology designed to enable scalable and deployable vaccine manufacturing without requiring extensive cold-chain storage infrastructure. This feature is particularly important for outbreak preparedness and rapid deployment in remote or resource-limited settings. Researchers also noted that the platform has previously demonstrated favorable tolerability in clinical investigations, strengthening confidence in its broader biodefense applications.
Following successful process development and GMP-grade manufacturing, HDT Bio submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. The company confirmed that HDT-321 received FDA clearance and is currently being evaluated in an ongoing Phase 1 clinical trial. Preliminary data generated in early 2026 reportedly show a strong safety profile and robust immunogenicity, representing a critical step toward potential future development and commercialization.
Biodefense Innovation Gains Global Importance
Company executives emphasized that advancing HDT-321 into clinical testing demonstrates the power of collaboration between biotechnology companies, academic institutions, and U.S. government agencies focused on national health security. HDT Bio leadership described the achievement as a major advancement in protecting populations against some of the world’s most dangerous infectious threats while establishing a broader vaccine platform for future public health emergencies.
In addition to the vaccine award, HDT Bio also received first place in the Health Security Innovation Pitch Challenge during the same event for its broad-spectrum antiviral development program. The recognition underscores increasing global attention on rapidly deployable antiviral and vaccine countermeasures amid ongoing viral outbreaks and emerging infectious disease risks worldwide.
Industry experts believe the success of HDT-321 highlights the growing role of clinical-stage biotechnology companies in supporting biodefense and pandemic preparedness initiatives. As governments continue investing in advanced medical countermeasure technologies, scalable vaccine platforms capable of rapid adaptation and deployment are expected to become increasingly valuable within the global healthcare and defense ecosystem.
The continued progress of HDT-321 may also help accelerate innovation in hemorrhagic fever vaccines, an area where approved treatment and prevention options remain limited despite increasing global disease surveillance concerns. With Phase 1 clinical development underway, HDT Bio and its partners are positioning the program as a potentially important tool in future outbreak response strategies.
Source: HDT Bio press release
